Eloxx Receives Another Orphan-Drug Designation for ELX-02

Eloxx Pharmaceuticals, Inc. (“Eloxx”),  (NASDAQ:ELOX), announced on 4/27/18 that it has received orphan-drug designation from the Food and Drug Administration (FDA) for ELX-02 for treatment of cystinosis from the FDA.